Pacira BioSciences, Inc. PCRX Weighted Average Exercise Price of Outstanding Options
Weighted Average Exercise Price of Outstanding Options at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.
The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacira BioSciences, Inc.'s weighted average exercise price of outstanding options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacira BioSciences, Inc.'s weighted average exercise price of outstanding options?
- Pacira BioSciences, Inc. (PCRX) reported weighted average exercise price of outstanding options of $40.25 in Q1 2026.
- How has Pacira BioSciences, Inc.'s weighted average exercise price of outstanding options changed year-over-year?
- Pacira BioSciences, Inc.'s weighted average exercise price of outstanding options decreased by 4.7% year-over-year, from $42.23 to $40.25.
- What is the long-term trend for Pacira BioSciences, Inc.'s weighted average exercise price of outstanding options?
- Over 5 years (2020 to 2025), Pacira BioSciences, Inc.'s weighted average exercise price of outstanding options has grown at a -2.4% compound annual growth rate (CAGR), from $45.98 to $40.65.
- What does weighted average exercise price of outstanding options mean?
- This metric calculates the average price at which holders of outstanding stock options can purchase company shares. It provides context on the 'in-the-money' status of employee compensation packages. When compared to the current market price, it helps assess the alignment between employee incentives and shareholder value.